NCT03611868
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03611868 |
| Title | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | Yes |
| Sponsors | Ascentage Pharma Group Inc. |
| Indications | |
| Therapies | |
| Age Groups: | senior | child | adult |
| Covered Countries | USA | AUS |
CKB BOOST